Autopsy report · NCT03298412
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
Cause of deathSlow enrollment
“Early Closure due to rare patient population”
Life of this trial
- Registered 8 months before it started.
- Ran for about 1 year 4 months before it stopped.
- 10 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Amgen
- Sponsor type
- Industry
- Conditions
- High-risk Diffuse Large B-cell Lymphoma
- Interventions
- Blinatumomab
- Participants
- 10
- Sites
- 32
- Countries
- Australia, Belgium, France, Greece, Italy, Switzerland, United States
Trials that died the same way
- Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
“Due to the rare patient population and challenges to enroll patients.” - Reiki for the Management of Neuropathic Pain
“Study closed due to substantial decrease in the desired patient population.” - A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer
“Closed due to slow patient accrual.” - Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
“Lack of patient population” - Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
“Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.